<DOC>
	<DOCNO>NCT00132925</DOCNO>
	<brief_summary>The purpose study : - To demonstrate efficacy daily administration Nasacort AQ 110 µg compare placebo child 2-5 year age perennial allergic rhinitis ; - To assess safety Nasacort AQ 110 µg child 2-5 year age .</brief_summary>
	<brief_title>An Efficacy Safety Evaluation Nasacort AQ Children Ages 2-5 Years With Perennial Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Subjects male female child age 25 year history least 1 year perennial allergic rhinitis ( PAR ) without seasonal allergic rhinitis ( SAR ) characterize nasal stuffiness , nasal discharge , sneeze , nasal itching , total eye symptom , verify positive skin test radioallergosorbent test ( RAST ) perennial allergen present subject 's environment ( documented historical testing perform past year accept ) . Subjects ( assist parent/guardian/care provider ) must meet aggregate symptom score least 18 ( possible 36 ) nasal stuffiness , nasal discharge sneeze reflective ( previous 24 hour ) instantaneous symptom score record morning Subjects must clinically relevant disease allergic rhinitis clinically relevant deviation normal physical examination . Subjects must recently expose rhinitis medication prior screen Subjects must history hypersensitivity glucocorticoid excipients formulation Subjects undergoing cosyntropin stimulation test must morning ( 8 AM ± 1 hour ) prestimulation serum cortisol level ≥ 5 µg/dL 30 minute poststimulation serum cortisol level ≥ 18 µg/dL screen Subjects present follow include study : Asthma , require chronic use inhale systemic corticosteroid previous 6 month ; upper respiratory tract infection sinus infection require antibiotic therapy within 2 week prior screen viral upper respiratory tract infection within 7 day screen . Nasal polyp , deviate septum , nasal/facial anatomic abnormality interfere symptom evaluation and/or use intranasal corticosteroid Treatment 2 course systemic corticosteroid ( course exceed 14 day ) within 1 year screening Use intranasal ocular corticosteroid within 2 week screen Use oral , inhaled , intravenous corticosteroid within 1 month screening Use intramuscular intraarticular corticosteroid within 3 month screen Use high potency dermatological corticosteroid within 1 month screening Use oral leukotriene modifier within 1 week screening Use nasal oral antihistamine oral nasal decongestant within 3 day screen Current history cataract glaucoma Treatment investigational product use investigational device within 1 month screen Immunotherapy , exception stable maintenance schedule , least 1 month prior screen History hypersensitivity glucocorticoid excipients formulation Subject investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol . Any waiver inclusion exclusion criterion must approve investigator sponsor casebycase basis prior enrol subject . This must document sponsor investigator . No subject allow enroll study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>allergic rhinitis</keyword>
</DOC>